KRASG12D

Overview

KRASG12D refers to a specific oncogenic variant of the KRAS gene product, in which glycine at codon 12 is replaced by aspartic acid. This mutation is one of the most clinically important KRAS alterations in cancer biology because it drives constitutive signaling through pathways that promote cell proliferation, survival, and tumor progression. In the context of pancreatic ductal adenocarcinoma (PDAC), KRASG12D is especially prominent and is repeatedly described in recent literature as the most common KRAS mutation in this disease.

Biologically, KRASG12D is considered a challenging therapeutic target because mutant KRAS proteins have high affinity for GTP and limited accessible binding pockets, making direct inhibition difficult. As a result, current research has explored multiple strategies to target KRASG12D, including small-molecule inhibitors, degraders, base editing, and nanoparticle-enabled delivery systems. These efforts also intersect with broader signaling networks such as MAPK1 and FGF2-PI3K-Akt1 signaling, and with combination approaches involving tumor suppressor pathways and DNA repair-related targets such as BRCA1, PARP1, and tumor protein p53.

Focus of Latest Publications

Recent studies have focused on KRASG12D as a central therapeutic target in pancreatic cancer and, more recently, in lung cancer. One study reported that an active fragment assembly strategy enabled rapid discovery of KRAS inhibitors, with preliminary assessments showing that compound 10b had significant inhibitory activity in pancreatic cancer cells harboring KRASG12C and KRASG12D mutations. This suggests that fragment-based medicinal chemistry can yield candidate inhibitors with activity against mutant KRAS-driven tumors.

Another publication reviewed CRISPR-mediated cancer therapies and highlighted KRASG12D inactivation via base editing. In this approach, engineered deaminases introduce precise single-nucleotide changes without generating double-strand breaks, offering a potentially more controlled way to disrupt the mutant allele. This work places KRASG12D among the leading examples of mutation-specific genome editing in oncology and underscores the relevance of CRISPR-Cas12a-based strategies for direct tumor targeting.

A clinical research article on vertical pathway inhibition addressed adaptive resistance to KRASG12D blockade in pancreatic cancer. It emphasized that oncogenic KRAS mutations occur in more than 90% of PDAC cases and that KRASG12D is the most common. The study’s framing indicates that blocking KRASG12D alone may be insufficient because tumors can adapt through downstream or parallel signaling routes, motivating combination strategies that suppress compensatory pathways.

A separate integrated in silico and in vitro study investigated natural compounds targeting KRAS G12D in pancreatic cancer. The authors noted that KRAS G12D mutations are among the most prevalent drivers of PDAC and remain difficult to target because of structural constraints and high GTP affinity. This work reflects ongoing interest in identifying noncanonical ligands or scaffolds that can engage the mutant protein through computational screening and experimental validation.

Most notably, a report in Cancer Discovery described an experimental PROTAC designed to degrade mutant KRASG12D. In a phase I trial, this degrader produced tumor responses in patients with advanced non-small cell lung cancer and pancreatic ductal adenocarcinoma, with limited toxicity. This is an important development because it extends KRASG12D targeting beyond inhibition toward targeted protein degradation, and it provides early clinical evidence that mutant KRASG12D can be therapeutically addressed in humans.

Across these studies, KRASG12D is consistently presented as a high-value but difficult target in PDAC and related cancers. The research landscape includes direct inhibition, degradation, genome editing, and delivery-enhanced therapeutic platforms, reflecting the need for multi-pronged approaches to overcome resistance and the biochemical properties of mutant KRAS.

Key Publications

Jun Active fragment assembly strategy enabling fast discovery of KRAS inhibitors against pancreatic cancer cells. (European journal of medicinal chemistry, 2026, PMID 41931988): "Preliminary assessments indicate that compound 10b exhibits significant inhibitory activity in pancreatic cancer cells harboring KRASG12C and KRASG12D mutations."
Jun Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026, PMID 41801133): "Oncogenic KRAS mutations are present in >90% of pancreatic ductal adenocarcinoma (PDAC), with KRASG12D being the most common."
May Identification of natural compounds targeting the KRAS G12D mutation in pancreatic cancer through integrated in silico and in vitro approaches. (Journal of computer-aided molecular design, 2026, PMID 42126708): "KRAS G12D mutations are among the most prevalent drivers of pancreatic ductal adenocarcinoma (PDAC) and remain challenging therapeutic targets due to their structural features and high GTP affinity."
May KRASG12D Degrader Shows Early Activity in Lung, Pancreatic Cancers. (Cancer discovery, 2026, PMID 41911322): "An experimental PROTAC drug designed to degrade mutant KRASG12D produced tumor responses in patients with advanced non-small cell lung cancer and pancreatic ductal adenocarcinoma in a phase I trial, with limited toxicity."
Apr CRISPR-mediated cancer therapies: Approaches to direct tumor targeting. (Critical reviews in oncology/hematology, 2026, PMID 41833894): "Key advances include KRASG12D inactivation via base editing, in which engineered deaminases introduce precise single-nucleotide changes without generating double-strand breaks;"